Beta-blockade intolerance in anthracyclin-induced cardiomyopathy
- 4 January 2006
- journal article
- research article
- Published by Elsevier BV in International Journal of Cardiology
- Vol. 106 (1), 132-134
- https://doi.org/10.1016/j.ijcard.2004.12.052
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: A report of the american college of cardiology/american heart association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) developed in collaboration with the international society for heart and lung transplantation endorsed by the heart failure society of americaJournal of the American College of Cardiology, 2001
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Doxorubicin‐induced cardiomyopathy treated with carvedilolClinical Cardiology, 1998
- Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patientsAmerican Heart Journal, 1995
- Reversibility of Severe Left Ventricular Dysfunction Due to Doxorubicin CardiotoxicityAnnals of Internal Medicine, 1987
- Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.Heart, 1986
- Reversible Doxorubicin-Induced Congestive Heart FailureArchives of Internal Medicine, 1982